Previous close | 11.72 |
Open | 11.60 |
Bid | 11.31 x 2800 |
Ask | 11.34 x 2800 |
Day's range | 11.01 - 11.69 |
52-week range | 3.21 - 18.33 |
Volume | |
Avg. volume | 9,063,665 |
Market cap | 3.159B |
Beta (5Y monthly) | 0.59 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.89 |
Earnings date | 07 May 2024 - 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 26.00 |
SAN CARLOS, Calif., April 19, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) (“Iovance” or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that on April 18, 2024 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 79,310 shares of Iovance’s common stock to thirty-seven new,
Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA ) is possibly approaching a major achievement in its business, so we would...
Iovance (IOVA) surges on the recent FDA approval for its lead pipeline drug as the first individualized, one-time cell therapy for certain patients with melanoma.